Sarcomas

Despite encouraging data shown in some subtypes, there is still a lot of work that still needs to be done with regard to determining the optimal use for immunotherapy in patients with sarcoma, a population that has historically been difficult to treat.

Though the use of next-generation sequencing (NGS) may not have immediate clinical implications for patients with sarcoma, it can provide valuable information for data collection and position patients for ongoing clinical trials that have the potential to push the needle forward, explained Gina Z. D'Amato, MD.

Adolescent and young adult patients fall between the 2 age groups that clinicians are used to seeing, leading to gaps in care and poor outcomes.

The presence of the proteins p16 and p21 has shown to be predictive of treatment response in patients with osteosarcoma, a disease that previously had no identified biomarkers to indicate whether or not patients would benefit from therapy, explained C. Parker Gibbs, MD.

The FDA has granted an accelerated approval to tazemetostat (Tazverik) for the treatment of adult and pediatric patients aged ≥16 years old with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.

Clinical hypnosis offers a non-pharmacological approach to managing chronic pain after cancer treatment.

The FDA recommends that no new patients with advanced soft tissue sarcoma (STS) be treated with olaratumab (Lartruvo) plus doxorubicin, following the negative results of the phase III ANNOUNCE trial.

The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) injection, a folate analog for 3 indications.

With antiretroviral drugs easing the burden of AIDS-defining cancers in HIV-positive patients, the most common cancers in this population are expected to shift to those associated with aging.

John E. Mullinax, M.D., discusses a chemotherapy strategy, isolated limb infusion, that may be able to save the limbs of some patients with sarcoma.

Trabectedin (Yondelis) chemotherapy was approved by the FDA for treatment of patients with specific metastatic soft tissue sarcomas-liposarcoma and leiomyosarcoma-who previously received chemotherapy that included an anthracycline.

A new study has shown that the risk of developing melanoma was more closely related to sun exposure in early life than in adulthood in young Caucasian women.